Emergent BioSolutions Inc.
EBS · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $507 | $123 | $592 | $2,326 |
| - Cash | $100 | $112 | $643 | $576 |
| + Debt | $676 | $860 | $1,406 | $841 |
| Enterprise Value | $1,083 | $871 | $1,355 | $2,591 |
| Revenue | $1,044 | $1,049 | $1,118 | $1,774 |
| % Growth | -0.5% | -6.1% | -37% | – |
| Gross Profit | $375 | $360 | $473 | $793 |
| % Margin | 36% | 34.3% | 42.3% | 44.7% |
| EBITDA | $53 | -$47 | $16 | $504 |
| % Margin | 5.1% | -4.5% | 1.4% | 28.4% |
| Net Income | -$191 | -$761 | -$212 | $220 |
| % Margin | -18.3% | -72.5% | -18.9% | 12.4% |
| EPS Diluted | -3.6 | -14.85 | -4.47 | 4.06 |
| % Growth | 75.8% | -232.2% | -210.1% | – |
| Operating Cash Flow | $59 | -$206 | -$34 | $321 |
| Capital Expenditures | -$23 | -$52 | -$116 | -$225 |
| Free Cash Flow | $36 | -$258 | -$150 | $96 |